<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Poxel Sa — News on 6ix</title>
    <link>https://6ix.com/company/poxel-sa-1</link>
    <description>Latest news and press releases for Poxel Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 30 Apr 2026 15:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/poxel-sa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5361fbeedb30cb6f6f0b7.webp</url>
      <title>Poxel Sa</title>
      <link>https://6ix.com/company/poxel-sa-1</link>
    </image>
    <item>
      <title>Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-postponement-of-the-publication-of-the-2025-annual-financial-statements-and-the-annual-financial-report</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-postponement-of-the-publication-of-the-2025-annual-financial-statements-and-the-annual-financial-report</guid>
      <pubDate>Thu, 30 Apr 2026 15:45:00 GMT</pubDate>
      <description>LYON, France, April 30, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company that leverages its expertise to develop innovative treatments for metabolic diseases, including certain rare diseases (the &quot;Company&quot;), announces the postponement of the publication of its annual financial statements for the fiscal year ended December 31, 2025, and its 2025 annual financial report.</description>
    </item>
    <item>
      <title>Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-sale-of-pxl770-to-scynexis-for-a-total-amount-of-up-to-dollar196-million-2</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-sale-of-pxl770-to-scynexis-for-a-total-amount-of-up-to-dollar196-million-2</guid>
      <pubDate>Tue, 31 Mar 2026 11:06:00 GMT</pubDate>
      <description>LYON, France, March 31, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and certain rare diseases, today announced that it has entered into a definitive agreement with SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company A U.S. pharmaceutical company specializing in the develo</description>
    </item>
    <item>
      <title>Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-confirms-the-drawdown-under-the-additional-tranche-d-pdr-bond-issue-as-part-of-the-continuation-plan-1</guid>
      <pubDate>Wed, 25 Mar 2026 20:58:00 GMT</pubDate>
      <description>LYON, France, March 25, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the &quot;Company&quot;), announces that it has signed, on March 25, 2026, the new Tranche D PDR subscription agreement with IPF Partners (&quot;IPF&quot;), for €3.75 million as part of the</description>
    </item>
    <item>
      <title>Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position-1</guid>
      <pubDate>Mon, 16 Feb 2026 18:02:00 GMT</pubDate>
      <description>LYON, France, February 16, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, reports today its annual revenue for the fiscal year ended December 31, 2025, and provides an update on its financial position.</description>
    </item>
    <item>
      <title>Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-implementation-of-an-equity-line-with-iris-capital-as-part-of-the-execution-of-the-recovery-plan-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-implementation-of-an-equity-line-with-iris-capital-as-part-of-the-execution-of-the-recovery-plan-1</guid>
      <pubDate>Tue, 03 Feb 2026 07:40:00 GMT</pubDate>
      <description>LYON, France, February 03, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the implementation of an equity line with IRIS, known as &quot;SmartATM® &quot; for a maximum amount of €5 million over five years (terms set out in the Appendix without this</description>
    </item>
    <item>
      <title>POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-sa-the-commercial-court-of-lyon-approves-the-recovery-plan-and-brings-an-end-to-the-judicial-reorganisation-proceedings-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-sa-the-commercial-court-of-lyon-approves-the-recovery-plan-and-brings-an-end-to-the-judicial-reorganisation-proceedings-1</guid>
      <pubDate>Fri, 30 Jan 2026 06:57:00 GMT</pubDate>
      <description>LYON, France, January 30, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the discharge from judicial reorganisation proceedings and ratification of the recovery plan by the Commercial Court of Lyon.</description>
    </item>
    <item>
      <title>Availability of Poxel’s 2025 Half-Year Financial Report</title>
      <link>https://6ix.com/company/poxel-sa-1/news/availability-of-poxels-2025-half-year-financial-report-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/availability-of-poxels-2025-half-year-financial-report-1</guid>
      <pubDate>Thu, 18 Dec 2025 18:05:00 GMT</pubDate>
      <description>LYON, France, December 18, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announced the availability of its half-year financial report as of June 30, 2025.</description>
    </item>
    <item>
      <title>Poxel Announces Results of its Combined General Meeting Held on December 11, 2025</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-announces-results-of-its-combined-general-meeting-held-on-december-11-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-announces-results-of-its-combined-general-meeting-held-on-december-11-2025-1</guid>
      <pubDate>Thu, 11 Dec 2025 18:42:00 GMT</pubDate>
      <description>LYON, France, December 11, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that it held its Combined General Meeting on Thursday, December 11, 2025, at 10:00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cou</description>
    </item>
    <item>
      <title>Poxel Publishes Its Financial Results for the First Half of 2025</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-publishes-its-financial-results-for-the-first-half-of-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-publishes-its-financial-results-for-the-first-half-of-2025-1</guid>
      <pubDate>Wed, 10 Dec 2025 07:52:00 GMT</pubDate>
      <description>LYON, France, December 10, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the &quot;Company&quot;), announces today its condensed consolidated half-year financial results for the period ended June 30, 2025 and provides an update on recent events ahead of its</description>
    </item>
    <item>
      <title>POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-sa-update-on-the-proposed-recovery-plan-and-organisation-of-a-webinar-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-sa-update-on-the-proposed-recovery-plan-and-organisation-of-a-webinar-1</guid>
      <pubDate>Mon, 24 Nov 2025 06:30:00 GMT</pubDate>
      <description>LYON, France, November 24, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the &quot;Company&quot;), provides an update on its proposed recovery plan and announces the organisation of a webinar.</description>
    </item>
    <item>
      <title>Poxel Announces That a Combined General Meeting Will Be Held on December 11, 2025 and the Availability of the Preparatory Documents</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-announces-that-a-combined-general-meeting-will-be-held-on-december-11-2025-and-the-availability-of-the-preparatory-documents-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-announces-that-a-combined-general-meeting-will-be-held-on-december-11-2025-and-the-availability-of-the-preparatory-documents-1</guid>
      <pubDate>Thu, 20 Nov 2025 23:00:00 GMT</pubDate>
      <description>LYON, France, November 20, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that a Combined General Meeting will be held on December 11, 2025, at 10:00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located</description>
    </item>
    <item>
      <title>Poxel Reports Revenue for the Third Quarter 2025</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-reports-revenue-for-the-third-quarter-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-reports-revenue-for-the-third-quarter-2025-1</guid>
      <pubDate>Thu, 13 Nov 2025 17:47:00 GMT</pubDate>
      <description>LYON, France, November 13, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reports its revenue for the quarter ended September 30, 2025, and for the first nine months of the fiscal year.</description>
    </item>
    <item>
      <title>POXEL SA: Update on the Draft Recovery Plan and Convening of the Annual General Meeting of Shareholders</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-sa-update-on-the-draft-recovery-plan-and-convening-of-the-annual-general-meeting-of-shareholders-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-sa-update-on-the-draft-recovery-plan-and-convening-of-the-annual-general-meeting-of-shareholders-1</guid>
      <pubDate>Wed, 05 Nov 2025 07:58:00 GMT</pubDate>
      <description>LYON, France, November 05, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders (the &quot;Company&quot;), today provides an update on its draft recovery plan and confirms the convening of its Annual General Meeting of Shareholders.</description>
    </item>
    <item>
      <title>Appointment of Yves Decadt as Member of Poxel’s Board of Directors</title>
      <link>https://6ix.com/company/poxel-sa-1/news/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/appointment-of-yves-decadt-as-member-of-poxels-board-of-directors-1</guid>
      <pubDate>Fri, 31 Oct 2025 17:52:00 GMT</pubDate>
      <description>LYON, France, October 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.</description>
    </item>
    <item>
      <title>Poxel: Availability of the 2024 Universal Registration Document</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-availability-of-the-2024-universal-registration-document-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-availability-of-the-2024-universal-registration-document-1</guid>
      <pubDate>Thu, 23 Oct 2025 16:16:00 GMT</pubDate>
      <description>LYON, France, October 23, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2024, has been filed with the French market aut</description>
    </item>
    <item>
      <title>Poxel: Availability of a First Document in Response to Questions Received From Shareholders</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-availability-of-a-first-document-in-response-to-questions-received-from-shareholders-2</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-availability-of-a-first-document-in-response-to-questions-received-from-shareholders-2</guid>
      <pubDate>Mon, 20 Oct 2025 15:45:00 GMT</pubDate>
      <description>LYON, France, October 20, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), informs that a first document in response to the questions received from the shareholders is available in French on the Company’s website, in the &quot;Investors&quot; section, &quot;Shareholder Info&quot;, &quot;Documentation&quot;.</description>
    </item>
    <item>
      <title>Poxel Reports Financial Results for Full Year 2024 and Provides Operational and Financial Update</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-reports-financial-results-for-full-year-2024-and-provides-operational-and-financial-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-reports-financial-results-for-full-year-2024-and-provides-operational-and-financial-update-1</guid>
      <pubDate>Thu, 16 Oct 2025 15:51:00 GMT</pubDate>
      <description>LYON, France, October 16, 2025--Regulatory News: Poxel (Paris:POXEL):</description>
    </item>
    <item>
      <title>Poxel Announces the Availability of a Bond Issue for a Maximum Amount of €2.5 Million</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-availability-of-a-bond-issue-for-a-maximum-amount-of-euro25-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-availability-of-a-bond-issue-for-a-maximum-amount-of-euro25-million-1</guid>
      <pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
      <description>LYON, France, September 29, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the availability of a bond issue for a maximum amount of €2.5 million to finance its observation period.</description>
    </item>
    <item>
      <title>Poxel Announces the Opening of Reorganization Proceedings</title>
      <link>https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-opening-of-reorganization-proceedings-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/poxel-announces-the-opening-of-reorganization-proceedings-1</guid>
      <pubDate>Fri, 08 Aug 2025 15:45:00 GMT</pubDate>
      <description>LYON, France, August 08, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces today the opening of reorganization proceedings.</description>
    </item>
    <item>
      <title>Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance</title>
      <link>https://6ix.com/company/poxel-sa-1/news/following-the-filing-for-the-opening-of-reorganization-proceedings-poxel-announces-changes-to-its-corporate-governance-1</link>
      <guid isPermaLink="true">https://6ix.com/company/poxel-sa-1/news/following-the-filing-for-the-opening-of-reorganization-proceedings-poxel-announces-changes-to-its-corporate-governance-1</guid>
      <pubDate>Fri, 01 Aug 2025 05:30:00 GMT</pubDate>
      <description>LYON, France, August 01, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, announces significant changes within the Board of Directors.</description>
    </item>
  </channel>
</rss>